BR0014491A - Bactérias atenuadas marcadas para tumor, composição farmacêutica, uso de bactérias atenuadas, e, proteina de fusão - Google Patents
Bactérias atenuadas marcadas para tumor, composição farmacêutica, uso de bactérias atenuadas, e, proteina de fusãoInfo
- Publication number
- BR0014491A BR0014491A BR0014491-6A BR0014491A BR0014491A BR 0014491 A BR0014491 A BR 0014491A BR 0014491 A BR0014491 A BR 0014491A BR 0014491 A BR0014491 A BR 0014491A
- Authority
- BR
- Brazil
- Prior art keywords
- tumor
- attenuated
- bacteria
- attenuated bacteria
- effector molecules
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/195—Chemokines, e.g. RANTES
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/51—Lyases (4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
"BACTéRIAS ATENUADAS MARCADAS PARA TUMOR, COMPOSIçãO FARMACêUTICA, USO DE BACTéRIAS ATENUADAS, E, PROTEìNA DE FUSãO". O presente pedido divulga a preparação e o uso de vetores bacterianos atenuados marcados para tumor para a liberação de uma ou mais moléculas efetoras primárias ao sítio de um tumor sólido. A(s) molécula(s) efetora(s) primária(s) da invenção é(são) usada(s) nos métodos da invenção para tratar um câncer de tumor sólido tal como um carcinoma, melanoma, linfoma ou sarcoma. A invenção diz respeito à surpreendente descoberta de que moléculas efetoras, que podem ser tóxicas quando sistemicamente administradas a um hospedeiro, podem ser localmente liberadas a tumores por bactérias atenuadas marcadas para tumor com toxicidade reduzida ao hospedeiro. O pedido também divulga a liberação de uma ou mais moléculas efetoras opcionais (denominadas moléculas efetoras secundárias) que podem ser liberadas pelas bactérias atenuadas marcadas para tumor em conjunção com a(s) molécula(s) efetora(s) primária(s).
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15758199P | 1999-10-04 | 1999-10-04 | |
US15750099P | 1999-10-04 | 1999-10-04 | |
US15763799P | 1999-10-04 | 1999-10-04 | |
PCT/US2000/023242 WO2001025397A2 (en) | 1999-10-04 | 2000-08-24 | Compositions and methods for tumor-targeted delivery of effector molecules |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0014491A true BR0014491A (pt) | 2004-03-09 |
Family
ID=27388022
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0014491-6A BR0014491A (pt) | 1999-10-04 | 2000-08-24 | Bactérias atenuadas marcadas para tumor, composição farmacêutica, uso de bactérias atenuadas, e, proteina de fusão |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP1261369A4 (pt) |
JP (1) | JP2004500042A (pt) |
KR (1) | KR20020059605A (pt) |
CN (1) | CN1420783A (pt) |
AU (1) | AU783714B2 (pt) |
BR (1) | BR0014491A (pt) |
CA (1) | CA2386465A1 (pt) |
IL (1) | IL148933A0 (pt) |
MX (1) | MXPA02003384A (pt) |
NZ (1) | NZ518354A (pt) |
WO (1) | WO2001025397A2 (pt) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1253551C (zh) | 1997-09-10 | 2006-04-26 | 维昂药品公司 | 减毒的遗传修饰肿瘤靶向细菌 |
US6080849A (en) | 1997-09-10 | 2000-06-27 | Vion Pharmaceuticals, Inc. | Genetically modified tumor-targeted bacteria with reduced virulence |
US6962696B1 (en) | 1999-10-04 | 2005-11-08 | Vion Pharmaceuticals Inc. | Compositions and methods for tumor-targeted delivery of effector molecules |
WO2003063593A1 (en) * | 2002-01-28 | 2003-08-07 | Vion Pharmaceuticals, Inc. | Methods for treating cancer by administering tumor-targetted bacteria and an immunomodulatory agent |
CA2869088A1 (en) * | 2002-02-07 | 2003-08-14 | Massachusetts Institute Of Technology | Anti-pathogen treatments |
EP2561887B8 (en) | 2003-01-14 | 2016-12-21 | Dana-Farber Cancer Institute, Inc. | Cancer therapy sensitizer |
AU2004289953B2 (en) | 2003-06-18 | 2008-09-25 | Genelux Corporation | Modified recombinant vaccina viruses and other microorganisms, uses thereof |
WO2005012363A1 (ja) * | 2003-08-01 | 2005-02-10 | Mochida Pharmaceutical Co., Ltd. | 標的化された炎症惹起剤 |
CN100435850C (zh) * | 2004-03-22 | 2008-11-26 | 中国医学科学院血液学研究所 | 具有放射保护和抗肿瘤作用的减毒沙门氏菌药物组合物 |
AU2006249235B2 (en) | 2004-05-14 | 2010-11-11 | Abraxis Bioscience, Llc | Sparc and methods of use thereof |
US8420603B2 (en) | 2004-05-14 | 2013-04-16 | Abraxis Bioscience, Llc | SPARC and methods of use thereof |
AU2005260697B2 (en) * | 2004-06-29 | 2011-10-06 | Anticancer, Inc. | Cancer selective auxotrophs |
ITRM20050422A1 (it) * | 2005-08-05 | 2007-02-06 | Consiglio Nazionale Ricerche | Fattori proteici dermonecrotizzanti di origine batterica e relativi usi in campo medico. |
US20080124355A1 (en) | 2006-09-22 | 2008-05-29 | David Gordon Bermudes | Live bacterial vaccines for viral infection prophylaxis or treatment |
US8357486B2 (en) | 2008-01-11 | 2013-01-22 | Genelux Corporation | Methods and compositions for detection of bacteria and treatment of diseases and disorders |
US8241623B1 (en) | 2009-02-09 | 2012-08-14 | David Bermudes | Protease sensitivity expression system |
US8524220B1 (en) | 2010-02-09 | 2013-09-03 | David Gordon Bermudes | Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria |
US8771669B1 (en) | 2010-02-09 | 2014-07-08 | David Gordon Bermudes | Immunization and/or treatment of parasites and infectious agents by live bacteria |
US9597379B1 (en) | 2010-02-09 | 2017-03-21 | David Gordon Bermudes | Protease inhibitor combination with therapeutic proteins including antibodies |
FR2960001A1 (fr) | 2010-05-12 | 2011-11-18 | Univ Rennes | Vecteur recombinant pour la production et la secretion de sequences d'acides amines d'interet par les bacteries propioniques et ses applications |
US9200251B1 (en) | 2011-03-31 | 2015-12-01 | David Gordon Bermudes | Bacterial methionine analogue and methionine synthesis inhibitor anticancer, antiinfective and coronary heart disease protective microcins and methods of treatment therewith |
CN102604949A (zh) * | 2011-04-12 | 2012-07-25 | 南京大学 | 一种乙醇脱氢酶启动子驱动的厌氧组织选择性基因表达方法及应用 |
WO2013128288A1 (en) * | 2012-02-27 | 2013-09-06 | Thelial Technologies S.A. | Monomeric bacterial actin adp-ribosyltransferases as cancer chemotherapeutics |
CN102731658B (zh) * | 2012-05-15 | 2014-07-30 | 山东大学 | 一种Tat PTD-Endostatin重组蛋白及其制备方法与应用 |
US9265804B2 (en) * | 2013-01-02 | 2016-02-23 | Decoy Biosystems, Inc. | Compositions and methods for treatment of cancer using bacteria |
US9593339B1 (en) | 2013-02-14 | 2017-03-14 | David Gordon Bermudes | Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment |
EP2829274A1 (en) | 2013-07-25 | 2015-01-28 | Institut National De La Recherche Agronomique | Vectors for producing and secreting substance of interest by bacteria and applications thereof |
US10987432B2 (en) * | 2013-09-05 | 2021-04-27 | The University Of Hong Kong | Therapeutic delivery and expression system, methods and uses thereof |
US9737592B1 (en) | 2014-02-14 | 2017-08-22 | David Gordon Bermudes | Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment |
US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
KR101685034B1 (ko) * | 2015-04-10 | 2016-12-09 | 전남대학교 산학협력단 | 고형암 조직 타겟팅 박테리아 및 그의 용도 |
US11723932B2 (en) | 2016-01-11 | 2023-08-15 | Synlogic Operating Company, Inc. | Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells |
CN107537027A (zh) * | 2016-06-23 | 2018-01-05 | 南开大学 | Tnfsf15蛋白在制备治疗黑色素瘤药物中的用途 |
SG11201906161VA (en) * | 2017-01-06 | 2019-08-27 | Synlogic Operating Co Inc | Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells |
CN107115533A (zh) * | 2017-04-01 | 2017-09-01 | 广州华津医药科技有限公司 | 基因工程菌vnp20009‑m在制备治疗恶性肉瘤药物中的应用 |
EP3651782A1 (en) * | 2017-07-12 | 2020-05-20 | Synlogic Operating Company, Inc. | Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells |
CN111278978B (zh) | 2017-09-08 | 2023-08-18 | 新实有限公司 | 使细菌能够通过葡萄糖依赖性生存力特异性靶向实体肿瘤的核酸系统 |
CN108314741B (zh) * | 2018-03-22 | 2021-08-03 | 中国人民解放军第四军医大学 | 一种肿瘤血管靶向抗癌肽nkl-dota及其制备方法 |
US11471497B1 (en) | 2019-03-13 | 2022-10-18 | David Gordon Bermudes | Copper chelation therapeutics |
CN110423772B (zh) * | 2019-07-17 | 2023-04-21 | 上海科技大学 | 一种用于鲍曼不动杆菌胞嘧啶碱基编辑质粒及其应用 |
WO2021178804A1 (en) * | 2020-03-06 | 2021-09-10 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Serum albumin binding nanobody compositions and methods for using the same |
US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
CN114438111B (zh) * | 2020-11-05 | 2023-08-11 | 深圳先进技术研究院 | Pp2严格厌氧沙门氏菌菌株构建及其在肿瘤治疗方面应用 |
EP4405488A1 (en) * | 2021-09-20 | 2024-07-31 | Pulmobiotics, S.L. | Genetically modified mycoplasma bacteria active against heterogenous bacterial biofilms |
CN116676324B (zh) * | 2023-07-28 | 2023-10-27 | 四川大学华西医院 | 基于Kil蛋白构建释放抗肿瘤效应蛋白的系统及方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0338679A3 (en) * | 1988-03-24 | 1991-03-06 | Genentech, Inc. | Tumour necrosis factor in the treatment of bladder cancer |
US6190657B1 (en) * | 1995-06-07 | 2001-02-20 | Yale University | Vectors for the diagnosis and treatment of solid tumors including melanoma |
WO1997008955A1 (en) * | 1995-09-06 | 1997-03-13 | Department Of The Army, Us Government | Bacterial delivery system |
US6080849A (en) * | 1997-09-10 | 2000-06-27 | Vion Pharmaceuticals, Inc. | Genetically modified tumor-targeted bacteria with reduced virulence |
CN1253551C (zh) * | 1997-09-10 | 2006-04-26 | 维昂药品公司 | 减毒的遗传修饰肿瘤靶向细菌 |
-
2000
- 2000-08-24 BR BR0014491-6A patent/BR0014491A/pt not_active Application Discontinuation
- 2000-08-24 MX MXPA02003384A patent/MXPA02003384A/es unknown
- 2000-08-24 CN CN00816714A patent/CN1420783A/zh active Pending
- 2000-08-24 IL IL14893300A patent/IL148933A0/xx unknown
- 2000-08-24 JP JP2001528552A patent/JP2004500042A/ja active Pending
- 2000-08-24 WO PCT/US2000/023242 patent/WO2001025397A2/en active IP Right Grant
- 2000-08-24 AU AU69334/00A patent/AU783714B2/en not_active Ceased
- 2000-08-24 EP EP00957764A patent/EP1261369A4/en not_active Withdrawn
- 2000-08-24 NZ NZ518354A patent/NZ518354A/en unknown
- 2000-08-24 CA CA002386465A patent/CA2386465A1/en not_active Abandoned
- 2000-08-24 KR KR1020027004371A patent/KR20020059605A/ko not_active Application Discontinuation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
Also Published As
Publication number | Publication date |
---|---|
CA2386465A1 (en) | 2001-04-12 |
AU783714B2 (en) | 2005-12-01 |
NZ518354A (en) | 2005-02-25 |
MXPA02003384A (es) | 2002-08-20 |
IL148933A0 (en) | 2002-09-12 |
EP1261369A2 (en) | 2002-12-04 |
WO2001025397A3 (en) | 2002-01-24 |
JP2004500042A (ja) | 2004-01-08 |
WO2001025397A2 (en) | 2001-04-12 |
KR20020059605A (ko) | 2002-07-13 |
CN1420783A (zh) | 2003-05-28 |
AU6933400A (en) | 2001-05-10 |
EP1261369A4 (en) | 2006-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0014491A (pt) | Bactérias atenuadas marcadas para tumor, composição farmacêutica, uso de bactérias atenuadas, e, proteina de fusão | |
BR0000003A (pt) | Azalidas e métodos de preparação das mesmas | |
CY1105953T1 (el) | Συνθεσεις για απελευθερωση συνδυασμων φαρμακων | |
BRPI0207961A8 (pt) | Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos. | |
TR199901417T2 (xx) | Analjezik etkisi olan yeni bile�imler. | |
BR0115109A (pt) | Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese | |
BR0112030A (pt) | Novos compostos que possuem atividade antibacteriana, antifúngica ou antitumor | |
BR0210028A (pt) | Agentes antibacterianos | |
GEP20043375B (en) | APRIL-Receptor (BCMA) and Use Thereof | |
BRPI0612845A8 (pt) | composto, formulação farmacêutica, métodos para tratar câncer e para sintetizar um composto de fórmula alq-dispasador | |
PT1033981E (pt) | Formulacoes e metodos para reduzir a toxicidade de agentes antineoplasicos | |
BRPI9809468B8 (pt) | Formulações farmacêuticas contendo voriconazol | |
BR0207487A (pt) | Método de tratamento de tumores em mamìferos e uso de compostos de epotilona | |
SE0104251D0 (sv) | Novel compounds | |
BR0318278A (pt) | compostos de éter aminocicloexìlico e usos dos mesmo | |
BRPI0510628A (pt) | polìmeros à base de celulose e acrìlicos, e uso dos mesmos para o tratamento de doenças infecciosas | |
BR0312845A (pt) | Tetratiomolibdato de tetrapropilamÈnio e compostos relacionados para terapias antiangiogênicas | |
BR9908510A (pt) | Uso de um composto, composto, processo para a preparação de um composto, composição farmacêutica, e, processo de tratar um paciente que sofre de, ou em risco de, uma doença micobacteriana | |
TR199900336T2 (xx) | EAA antagonistleri olarak tetrahidrokinolin t�revleri. | |
WO1997004788A3 (en) | Use of calendula glycosides for the treatment of psoriasis | |
NO990833D0 (no) | Farmas°ytiske forbindelser | |
DE60301339D1 (de) | Pyrazolopyrimidin- und pyrazolotriazinderivate und diese enthaltende pharmazeutische zubereitungen | |
BR0208017A (pt) | Combinação compreendendo combretastatina e agentes anticâncer | |
BR9510490B1 (pt) | composição farmacêutica combinada de dois componentes estruturada para uso em um hospedeiro. | |
AR043071A1 (es) | Uso de macrolidos para el tratamiento del cancer y degeneracion macular y una composicion farmaceutica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B11E | Dismissal acc. art. 34 of ipl - requirements for examination incomplete | ||
B11T | Dismissal of application maintained [chapter 11.20 patent gazette] |